Page last updated: 2024-12-05

sulfoxone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfoxone is an anti-inflammatory and anti-infective agent that has been studied for its potential use in the treatment of various conditions, including leprosy, tuberculosis, and inflammatory bowel disease. Its synthesis typically involves the reaction of 4,4'-diaminodiphenyl sulfone with a suitable oxidizing agent, such as hydrogen peroxide. The mechanism of action of sulfoxone involves the inhibition of bacterial enzymes involved in the synthesis of essential metabolites. Sulfoxone has shown promising results in preclinical studies, exhibiting anti-inflammatory and anti-infective properties. However, its clinical use is limited due to potential side effects, including hemolytic anemia, and the development of more effective and safer alternatives. Research on sulfoxone continues, exploring its potential for treating various inflammatory conditions and its synergistic effects with other therapeutic agents.'

sulfoxone: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5351
CHEMBL ID1570
CHEBI ID135651
SCHEMBL ID155723
MeSH IDM0110246

Synonyms (22)

Synonym
[4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid
sulfoxone
aldesulfone
aldesulphone
DB01145
CHEBI:135651
CHEMBL1570
144-76-3
[(4-{4-[(sulfinomethyl)amino]benzenesulfonyl}phenyl)amino]methanesulfinic acid
unii-0g3c18oh4d
0g3c18oh4d ,
methanesulfinic acid, (sulfonylbis(4,1-phenyleneimino))bis-
aldesulfon
(sulfonylbis(4,1-phenyleneimino))dimethanesulfinic acid
aldesulfone [who-dd]
SCHEMBL155723
NEDPPCHNEOMTJV-UHFFFAOYSA-N
DTXSID80162594
{[4-({4-[(sulfinomethyl)amino]benzene}sulfonyl)phenyl]amino}methanesulfinic acid
((sulfonylbis(4,1-phenylene))bis(azanediyl))dimethanesulfinic acid
Q7636216
EN300-18535974
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (75.00)18.7374
1990's0 (0.00)18.2507
2000's6 (15.00)29.6817
2010's4 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.92 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.85%)6.00%
Case Studies2 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other48 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]